Key result
Ankura ePTFE endograft TEVAR is linked to postimplantation syndrome in ~9% of elective patients.
Why the study?
The study aimed to describe postimplantation syndrome (PIS)-compatible inflammatory findings, C-reactive protein (CRP) status, and postoperative hospitalization after elective thoracic endovascular aortic repair (TEVAR) with the Ankura expanded polytetrafluoroethylene (ePTFE) endograft.
What is the frequency of postimplantation syndrome (PIS)-compatible inflammatory findings, perioperative C-reactive protein trajectory, and postoperative hospitalization duration in patients undergoing elective standard TEVAR with the Ankura ePTFE endograft?
Observational (n=80)
No
What is the frequency of postimplantation syndrome (PIS)-compatible inflammatory findings, perioperative C-reactive protein trajectory, and postoperative hospitalization duration in patients undergoing elective standard TEVAR with the Ankura ePTFE endograft?
In patients undergoing elective TEVAR with an Ankura ePTFE endograft, PIS-compatible inflammatory findings occurred in 8.8% of cases and were associated with longer unadjusted hospital stays (median 11 vs. 2 days), though postoperative CRP elevation (>10 mg/L) was much more common (60.0%) and declined significantly before discharge.
Answers are grounded in this paper and cite their sources.
May extend hospital stay after TEVAR; leaves open whether ePTFE grafts reduce PIS versus other materials.
Objectives We described postimplantation syndrome (PIS)-compatible inflammatory findings, C-reactive protein (CRP) status, and postoperative hospitalization after elective thoracic endovascular aortic repair (TEVAR) with the Ankura expanded polytetrafluoroethylene (ePTFE) endograft. Patients and methods This retrospective study included 80 patients undergoing first-time elective TEVAR in 2024-2025. Hospital identifiers were reviewed to distinguish patients with matching deidentified records. Seven met a coded screening rule and had chart-supported fever ≥38.5 °C for ≥48 hours, leukocytosis >14×10 9 /L, CRP >10 mg/L, and procalcitonin <0.1 ng/mL. They were classified as having PIS-compatible inflammatory findings because infection was not fully excluded. Paired binary CRP status and unadjusted hospital stay were examined. Results Seven patients (8.8%; 95% confidence interval, 4.3-17.0%) had PIS-compatible inflammatory findings; fever began on postoperative day 1. CRP elevation decreased from 48/80 (60.0%) after TEVAR to 29/80 (36.3%) before discharge (exact McNemar p<0.001). Median stay was 11 vs. 2 days (unadjusted p<0.001). Early discharge limited documentation of 48-hour fever, and symptom and marker improvement influenced discharge. Hematoma revision and transient neurological deficit provided other potential reasons for prolonged stay in two affected patients. Conclusion This Ankura ePTFE series provides preliminary descriptive information on PIS-compatible inflammatory findings and inpatient CRP status after elective TEVAR. The hospitalization contrast cannot be attributed to inflammation alone, and the findings do not establish definitive PIS incidence, independent risk factors, or a protective graft-material effect.
No takes yet. Share an insight, caveat, or question.
Külahçıoğlu et al. (2026) conducted an observational in Thoracic aortic disease requiring elective standard thoracic endovascular aortic repair (TEVAR) (n=80). Elective standard TEVAR with the Ankura ePTFE endograft vs. Patients without PIS-compatible inflammatory findings (n=73) was evaluated on Proportion of patients with postimplantation syndrome (PIS)-compatible inflammatory findings (fever >=38.5 °C for >=48 hours, leukocytosis >14x10^9/L, CRP >10 mg/L, and procalcitonin <0.1 ng/mL) (8.8%, 95% CI 4.3-17.0). Elective TEVAR with the Ankura ePTFE endograft was associated with PIS-compatible inflammatory findings in 8.8% (95% CI, 4.3-17.0%) of patients and a median hospital stay of 11 vs. 2 days (p<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: